الفهرس 
BREAST CANCEROnly 14 pages are availabe for public view
 |  | from | 99 |  |  |
| | | from | 99 | | |
Abstract
The presence of different molecular subtypes is what characterize the biodiversity of Breast cancer. As medicine is continuously improving and shifting to a more personalized approach, it is mandatory to understand the nature and characteristics of different molecular subtypes.
According to the presence or absence of hormonal receptors such as estrogen and progesterone or the amplification of HER2 neu and the level of the proliferation marker Ki67, breast cancer can be classified into Luminal A, Luminal B, HER2 enriched and triple negative.
There are many clinicopathological and therapeutic features that characterize different luminal subtypes. For instance, luminal A and B are much frequent than HER2 enriched and TNBC in our study as well as in the general population and they tend to respond to hormonal therapy. However, Her2 positive tumors are usually treated with anti Her2/neu therapy and TNBC treatment include mainly chemotherapy and radiotherapy. Better prognosis is usually attributed to luminal A and B at early stages compared to HER2 enriched and TNBC that usually present at later stage and show aggressive course of the disease.